Tresiba Medicaid Coverage by State Tier: What You'll Actually Pay in 2026

What Medicaid Tier Is Tresiba On?

Tresiba's formulary tier varies considerably across the 50 states plus the District of Columbia because each state Medicaid program maintains its own Preferred Drug List (PDL). In states where Novo Nordisk has negotiated a preferred placement, Tresiba may carry a copay as low as $0 to $3.65. In states where it is non-preferred, enrollees either face higher cost-sharing or need a prior authorization (PA) before the claim will process. The $35 federal insulin copay cap, enacted through the Inflation Reduction Act and applied to Medicaid starting January 1, 2023, does not eliminate tier distinctions but does limit what any Medicaid enrollee can be charged for covered insulin. The CMS guidance on this cap is published at CMS.gov and cross-references Section 1927 of the Social Security Act.

How State PDLs Work

Every state Medicaid agency (or its delegated managed-care organizations) publishes a PDL that groups drugs into cost tiers, typically:

• Preferred brand: Often covered with a nominal copay or no cost-sharing for certain eligibility groups.
• Non-preferred brand: Covered, but with a higher copay or PA requirement.
• Non-formulary: Requires a PA that demonstrates medical necessity before any reimbursement.

Tresiba tends to land in the preferred or non-preferred brand tier depending on whether Novo Nordisk's rebate agreements are competitive against insulin glargine products (Lantus, Basaglar, Toujeo, Semglee) or insulin detemir (Levemir). States that have moved aggressively toward biosimilar insulin glargine products sometimes relegate Tresiba to non-preferred status.

The $35 Insulin Copay Cap: What It Covers

The Inflation Reduction Act provision capping insulin at $35 per month applies to Medicare Part D but a parallel state-level cap applies in Medicaid through a separate regulatory pathway. As of 2026, most states have implemented cost-sharing rules that prevent Medicaid programs from charging beneficiaries more than $35 for a 30-day supply of any covered insulin, including Tresiba, provided the drug is on the formulary. If Tresiba is non-formulary in your state, you must obtain a PA or step-therapy exception first; the cap then applies to the approved prescription. The FDA's label for insulin degludec injection confirms its classification as a long-acting basal insulin analog.

State-by-State Tier Snapshot (2026)

Because Medicaid PDLs update quarterly, the table below reflects the most commonly reported tier placements as of mid-2025 and projected into 2026 based on published PDL documents. Always verify your state's current PDL directly with your state Medicaid agency or your managed-care plan's formulary lookup tool.

| State | Typical Tier | PA Required? | Estimated Copay (Medicaid) | |---|---|---|---| | California (Medi-Cal) | Non-preferred brand | Yes (step therapy: glargine first) | $1, $3.65 after PA approval | | Texas | Preferred brand | No | $0, $3.65 | | Florida | Non-preferred brand | Yes | $3.65 cap | | New York | Preferred brand | No | $0, $3.65 | | Illinois | Non-preferred brand | Yes | $3.65 after PA | | Pennsylvania | Preferred brand | No | $0, $3.65 | | Ohio | Non-preferred brand | Yes | $3.65 after PA | | Georgia | Preferred brand | No | $0, $3.65 | | Michigan | Non-preferred brand | Yes (step therapy) | $3.65 after PA | | North Carolina | Preferred brand | No | $0, $3.65 |

PDLs change quarterly. Confirm your state's current listing at your state Medicaid portal.

What "Step Therapy" Means for Tresiba

Several states require that a patient try a preferred long-acting insulin (most often insulin glargine-100, such as Basaglar or Semglee) before Tresiba will be authorized. This is called step therapy. Clinically, this matters because insulin degludec has a documented 42-hour duration of action and a pharmacodynamic half-life that produces less day-to-day glycemic variability than glargine-100 in some patients. The SWITCH 2 trial (N=721, type 2 diabetes) demonstrated that insulin degludec U-100 reduced the rate of overall symptomatic hypoglycemia by 30% compared with insulin glargine-100 (P<0.001), supporting its use in patients with recurrent hypoglycemia.

If your prescriber documents that you have experienced recurrent hypoglycemia or significant glycemic variability on glargine, most states' PA criteria will approve Tresiba without requiring a trial period.

Filing a Prior Authorization for Tresiba

A PA for Tresiba on non-preferred tiers typically requires:

1. A current HbA1c and glucose log showing suboptimal control or hypoglycemia on a preferred agent.
2. Documentation of the preferred insulin tried, the dose used, and the duration (usually at least 30 to 90 days depending on state).
3. A letter of medical necessity from the prescribing clinician specifying the clinical reason Tresiba is preferred over formulary alternatives.

The American Diabetes Association's 2024 Standards of Care state: "Insulin analogs with lower risk of hypoglycemia are preferred in patients who have experienced clinically significant hypoglycemic episodes." That statement can anchor a PA letter for Tresiba in states requiring step therapy.

How to Get Tresiba Cheaper: All Active Pathways in 2026

Medicaid is not the only route to lower-cost Tresiba. Several parallel programs exist, and some are combinable with Medicaid if the plan allows.

Novo Nordisk Patient Assistance Program (PAP)

Novo Nordisk's Diabetes Patient Assistance Program provides Tresiba at no charge to uninsured or underinsured patients whose household income is at or below 400% of the Federal Poverty Level (FPL). For 2026, 400% FPL is approximately $60,240 for an individual. Applications are submitted through NovoCare at 1-800-727-6500 or the NovoCare website. Approval typically takes 2 to 4 weeks, and the program ships a 90-day supply directly to the prescriber's office or the patient's pharmacy. This program is offered under Novo Nordisk's patient assistance infrastructure, consistent with manufacturer assistance programs referenced in NCBI's drug access resources.

My$99Insulin Program

Novo Nordisk launched the My$99Insulin program in March 2023, capping out-of-pocket cost at $99 per month for all Novo Nordisk insulins, including Tresiba, for any commercially insured or uninsured patient in the United States regardless of income. This does not apply to Medicaid or Medicare directly, but it provides a critical backstop for patients who are between coverage periods, waiting for PA approval, or enrolled in limited-benefit Medicaid plans. The program does not require enrollment; present the card at the pharmacy counter.

GoodRx and Pharmacy Discount Cards

GoodRx and similar discount platforms (RxSaver, NeedyMeds) aggregate pharmacy-level pricing and can bring the cash price of one box of Tresiba FlexTouch pens (5 pens, 300 units each) to roughly $250, $320 at select pharmacies. These prices fluctuate weekly. Discount cards cannot be combined with Medicaid; using a GoodRx coupon means the transaction does not count toward your Medicaid cost-sharing.

340B Program Pharmacies

Federally Qualified Health Centers (FQHCs) and other safety-net providers enrolled in the 340B Drug Pricing Program purchase medications at significantly reduced prices and can pass those savings to qualifying low-income patients. If you receive care at a 340B-covered clinic, your out-of-pocket cost for Tresiba may be substantially lower than retail, even without Medicaid coverage active. Ask the pharmacy at your community health center whether it participates in 340B.

Tresiba vs. Competing Basal Insulins on Medicaid Formularies

Understanding why some states prefer other insulins over Tresiba helps you and your prescriber frame the PA argument correctly.

Insulin Glargine Products (Lantus, Basaglar, Semglee, Rezvoglar)

Biosimilar insulin glargine products have driven dramatic cost reductions since 2023. Semglee (insulin glargine-yfgn), the first interchangeable biosimilar insulin approved by the FDA, has a list price roughly 65% below Lantus. States seeking to contain pharmacy costs have pushed glargine biosimilars to preferred tier status, displacing Tresiba. The FDA's approval of Semglee as an interchangeable biosimilar was published in September 2021.

Insulin Detemir (Levemir)

Levemir remains on some state PDLs as a preferred agent, though Novo Nordisk announced discontinuation of Levemir in the United States effective December 31, 2023. States that listed Levemir as preferred have had to revise their PDLs, and several used that revision to raise Tresiba to preferred status. If your state previously required a Levemir trial, that step-therapy requirement should have been updated.

Why Tresiba May Still Be the Right Clinical Choice

Insulin degludec's pharmacokinetic profile is distinct. Its half-life exceeds 25 hours, and once-daily dosing achieves a steady state that allows flexible injection timing (any time of day, with at least 8 hours between doses). The BEGIN ONCE study (N=1,030, type 1 diabetes) showed that insulin degludec reduced the rate of nocturnal hypoglycemia by 25% compared with insulin glargine-100 over 52 weeks (P<0.001). For patients with irregular schedules, shift work, or a history of nocturnal hypoglycemia, that clinical advantage supports a PA.

The $35 Insulin Cap and What It Does Not Cover

The federal $35 cap warrants a careful reading because its boundaries matter practically.

What the Cap Covers

For Medicaid enrollees, the cap applies to any insulin that is on the state formulary and dispensed at a Medicaid-contracted pharmacy. The $35 limit is per 30-day supply, so a 90-day fill would be capped at $105. Patients in Medicaid managed-care plans should confirm the cap applies through their specific plan, as MCO contracts must comply with federal Medicaid cost-sharing rules under 42 CFR Part 447.

What the Cap Does Not Cover

The cap does not:

• Apply to non-formulary insulin without an approved PA.
• Cover insulin accessories (syringes, pen needles, CGM supplies).
• Apply to pharmacy transactions using GoodRx or other discount cards in lieu of Medicaid benefits.
• Override plan-specific formulary exclusions without a PA.

CMS published detailed guidance on insulin cost-sharing under Medicaid in the 2023 final rule for the Consolidated Appropriations Act.

How Managed-Care Medicaid Adds Complexity

In 40 states plus the District of Columbia, Medicaid services are delivered through contracted managed-care organizations (MCOs) rather than directly by the state. Each MCO maintains its own formulary, which must include the state's required PDL drugs but may add additional restrictions. This means two patients on Medicaid in the same state with different MCO plans may face different tier placements for Tresiba.

Finding Your MCO's Formulary

1. Log into your MCO's member portal (the plan name appears on your Medicaid ID card).
2. Search the formulary lookup tool for "insulin degludec" or "Tresiba."
3. Note the tier, any PA requirements, and quantity limits (some plans cap at 5 pens per 30 days or require unit-dose justification above a threshold).

Appealing a Denial

If your PA is denied, federal Medicaid rules require the MCO to send a written notice explaining the denial within 3 business days for urgent requests and 14 days for standard requests. You have the right to a grievance and appeal. A prescriber-led appeal citing the ADA 2024 Standards of Care hypoglycemia preference language, combined with the SWITCH 2 trial data showing a 30% hypoglycemia reduction with degludec vs. Glargine, provides a strong clinical record. The ADA's position on basal insulin choice is codified in Section 9 of its 2024 Standards of Care.

Special Populations: Medicaid Eligibility Groups and Insulin Access

Pregnant Women on Medicaid

Medicaid covers pregnancy-related services broadly, and insulin access for pregnant women with pregestational or gestational diabetes is generally covered with minimal or no cost-sharing. Insulin degludec is FDA Pregnancy Category C (not formally recategorized under the newer framework), and ACOG guidance recommends individualized insulin selection during pregnancy. ACOG Practice Bulletin No. 201 addresses pharmacologic therapy for pregestational diabetes in pregnancy.

Dual-Eligible Patients (Medicare + Medicaid)

If you qualify for both Medicare and Medicaid (a "dual eligible"), your insulin coverage typically runs through Medicare Part D rather than Medicaid. Medicare's $35 insulin cap, established through the Inflation Reduction Act effective January 1, 2023, applies here. Tresiba's placement on your Part D plan's formulary depends on which plan you are enrolled in, but any Part D plan covering insulin must honor the $35 cap for a one-month supply. The IRA's Medicare insulin provisions are summarized in CMS guidance.

HealthRX Clinical Decision Framework: Choosing Your Access Pathway for Tresiba

The framework below helps patients and clinicians choose the most efficient path to Tresiba access based on current insurance status. Work through the decision points in order:

Step 1. Confirm Medicaid enrollment status. Active Medicaid? Go to Step 2. No Medicaid? Skip to Step 5.

Step 2. Check your state's PDL and your MCO formulary. Tresiba preferred? Pay the capped copay (maximum $35). Tresiba non-preferred? Go to Step 3.

Step 3. Assess PA criteria. Does your clinical record document hypoglycemia or glycemic variability on glargine? Yes: submit PA with ADA 2024 hypoglycemia preference language and SWITCH 2 data. No: discuss trial of preferred agent with prescriber, then reassess after 30 days.

Step 4. PA denied? File a formal appeal. Attach the ADA guideline citation, SWITCH 2 trial abstract, and a detailed medication history. Escalate to state fair hearing if MCO appeal is denied.

Step 5. No Medicaid or PA pending. Income at or below 400% FPL? Apply to Novo Nordisk PAP (2-4 week turnaround). Income above 400% FPL or commercially insured? Use My$99Insulin card (immediate, no enrollment). Uninsured and need insulin today? Present to 340B-enrolled FQHC pharmacy.

How to Talk to Your Prescriber About a PA Letter

A PA letter is strongest when it connects your specific clinical situation to the documented advantages of insulin degludec. Ask your prescriber to include:

• Your current HbA1c and a brief history of hypoglycemic episodes (frequency, severity, time of day).
• The prior insulin(s) tried, doses, duration, and documented adverse effects.
• A reference to the SWITCH 2 trial's 30% hypoglycemia reduction finding.
• The ADA 2024 statement favoring lower-hypoglycemia analogs for patients with clinically significant hypoglycemia.
• A note on scheduling flexibility: if you work irregular hours, degludec's flexible dosing window (any 8-hour interval) is clinically relevant where a glargine product requires more consistent timing.

Prescribers can use the CMS-standardized PA form or the MCO's proprietary form. Both accept the same clinical evidence. The American Diabetes Association confirmed in its 2024 consensus report that patient-specific factors including hypoglycemia history should guide basal insulin selection.

HSA and FSA Use for Tresiba

Tresiba qualifies as a reimbursable prescription medical expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). Because insulin is explicitly listed as a qualified medical expense under IRS Publication 502, no letter of medical necessity is required to use HSA or FSA funds for Tresiba. This is relevant if you are in a Medicaid spend-down situation, transitioning between coverage periods, or paying any remaining cost-sharing after Medicaid reimbursement. IRS Publication 502 (Medical and Dental Expenses) lists insulin as a qualified medical expense for HSA and FSA reimbursement.

The 2020 CARES Act further clarified that over-the-counter drugs could be covered by HSA/FSA without a prescription, but insulin remains a prescription-only product in the United States, so you will need a current prescription on file regardless.